BiotechTube
ForwardVue Pharma

ForwardVue Pharma

San Diego, United States· Est.
forwardvuepharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ForwardVue Pharma is developing a novel, long-acting ORAI1 blocker designed to treat retinal neovascular diseases through a VEGF-independent mechanism. The lead candidate aims to achieve a dosing regimen of only 1-2 intravitreal injections per year, significantly reducing the treatment burden compared to current anti-VEGF standards. Founded and led by a practicing vitreoretinal surgeon-scientist, the company is in the preclinical stage with a patent-protected platform. Its approach targets pathways both upstream and downstream of VEGF, potentially offering a new therapeutic option for patients with inadequate responses to existing therapies.

OphthalmologyRetinal Diseases

Technology Platform

VEGF-independent drug delivery platform centered on long-acting ORAI1 calcium channel blockers for durable treatment of retinal neovascularization.

Opportunities

The primary opportunity is to disrupt the multi-billion dollar retinal disease market by offering a therapy with a dramatically reduced injection burden (1-2 per year) compared to current anti-VEGF standards.
A VEGF-independent mechanism also addresses the significant unmet need of patients who are poor responders to existing therapies.

Risk Factors

Key risks include the preclinical scientific risk of a novel ORAI1 mechanism failing to translate clinically, high competition from established and next-generation therapies, and financial risk associated with securing sufficient funding to advance through costly clinical development.

Competitive Landscape

ForwardVue operates in the highly competitive retinal therapeutics space, competing directly with major pharma's anti-VEGF franchises and a wave of companies developing longer-acting anti-VEGF agents, gene therapies, and sustained-release implants. Its differentiation hinges on its VEGF-independent mechanism and proposed durability.

More companies in Drug Delivery & Formulation →More companies in United States →